Missing Data: One Long-Term Lesson From US FDA Action On Hydroxychloroquine

Politicization of COVID-19 treatments is one of the unexpected wrinkles amid an unprecedented pandemic. But one lesson from the hydroxychloroquine experience in the US is more typical if still troubling: almost no one followed the rules on reporting follow-up data.

DATA_Puzzle Piece_186976547_1200.jpg

The US Food and Drug Administration’s handling of the authorization allowing emergency use of hydroxychloroquine and chloroquine for treatment of COVID-19 will inevitably be viewed as a test of the agency’s independence in the context of the Trump Administration.

The 15 June revocation of the EUA granted for the products will certainly weigh heavily in favor of FDA’s independence...

More from Post-Marketing Regulation & Studies

More from Product Reviews

Gene Therapy Elevidys Among Six Orphan Drugs Awaiting EU Marketing Verdict

 
• By 

The European Medicines Agency is expected to decide whether to recommend EU-wide marketing authorization for six orphan-designated medicines that are all already approved in the US.

Business Background Of New CDER Director George Tidmarsh

 

George Tidmarsh has extensive experience in the biopharmaceutical industry and led several drugs to FDA approval.

World’s First Hemato-Oncology Microbiota Therapeutic Among Latest New EU Filings

 

The European Medicines Agency has started reviewing for potential EU marketing approval six new products, including MaaT Pharma’s microbiota therapeutic for acute-graft-versus-host disease, and AstraZeneca's camizestrant for locally advanced or metastatic breast cancer.